Asahi Intecc Co., Ltd. concluded an exclusive sales agreement in Japan for the embolic agent “Nexsphere-F\u2122” from Korea’s NEXTBIOMEDICAL on April 9, 2026. The contract period is five years following insurance listing, with no impact on consolidated results for the current fiscal year.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7747","jir_company_name":"Asahi Intecc Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-04-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/7747-20260409-01.pdf","jir_short_summary":"Asahi Intecc Co., Ltd. concluded an exclusive sales agreement in Japan for the embolic agent \"Nexsphere-F\u2122\" from Korea's NEXTBIOMEDICAL on April 9, 2026. The contract period is five years following insurance listing, with no impact on consolidated results for the current fiscal year.","jir_summary":"### Contract Overview\nAsahi Intecc Co., Ltd. concluded an exclusive sales agreement in Japan on April 9, 2026, for the embolic agent \"Nexsphere-F\u2122\" developed and manufactured by Korea's NEXTBIOMEDICAL CO., LTD. Although the product is not yet approved by regulatory authorities, the company aims for insurance listing after obtaining regulatory approval and plans to start direct sales to hospitals through consolidated subsidiaries. The contract period is five years following insurance listing, with expectations for annual renewal thereafter.\n\n### Future Outlook and Impact\n\"Nexsphere-F\u2122\" is already marketed in direct sales regions in Europe and is used in TAME treatments. Leveraging its relationships with physicians and sales network, Asahi Intecc anticipates the spread of this product and synergies with related products. There is no impact expected on the consolidated results for the current fiscal year from this contract. The company aims to contribute to improving the quality of life for chronic pain patients by offering new treatment options.","jir_financial_highlights":"Contract Signing Date: 2026\u5e744\u67089\u65e5 (Unknown)\nContract Period: Five years after insurance listing (assumed annual renewal) (Unknown)\nImpact on Current Consolidated Results: None (Unknown)","jir_category":"","jir_hashtags":"#AsahiIntecc, #M&A, #MedicalDevices, #JapaneseStocks","jir_key_figures":"Contract Signing Date: 2026\u5e744\u67089\u65e5\nContract Period: Five years after insurance listing (assumed annual renewal)\nImpact on Current Consolidated Results: None","jir_meta_title":"Asahi Intecc Concludes Exclusive Sales Agreement in Japan for Embolic Agent \"Nexsphere-F\u2122\" from Korea's NEXTBIOMEDICAL","jir_meta_description":"On April 9, 2026, Asahi Intecc Co., Ltd. concluded an exclusive sales agreement in Japan for the embolic agent \"Nexsphere-F\u2122\" from Korea's NEXTBIOMEDICAL. The contract period is five years following insurance listing, with no impact on consolidated results for the current fiscal year.","jir_og_title":"Asahi Intecc Concludes Exclusive Sales Agreement in Japan for Embolic Agent \"Nexsphere-F\u2122\"","jir_og_description":"Exclusive sales of Korea's NEXTBIOMEDICAL's embolic agent \"Nexsphere-F\u2122\" in Japan. Expected to become a new treatment option for chronic pain.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7656,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-39769","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n